Targeting HER2 protein in individual cells using ICP-MS detection and its potential as prognostic and predictive breast cancer biomarker
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting HER2 protein in individual cells using ICP-MS detection and its potential as prognostic and predictive breast cancer biomarker
Authors
Keywords
HER2, Cell targeting, Single cell ICP-MS, Antibody labelling, Breast cancer, Biomarkers
Journal
TALANTA
Volume 235, Issue -, Pages 122773
Publisher
Elsevier BV
Online
2021-08-08
DOI
10.1016/j.talanta.2021.122773
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis
- (2019) Gabriele De Rubis et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry
- (2019) Daniel E. Carvajal-Hausdorf et al. CLINICAL CANCER RESEARCH
- Molecular Classification of Breast Cancer
- (2019) Julia Y.S. Tsang et al. ADVANCES IN ANATOMIC PATHOLOGY
- [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification
- (2019) Naoki Takegawa et al. INTERNATIONAL JOURNAL OF CANCER
- Quantitative Analysis of Transferrin Receptor 1 (TfR1) in Individual Breast Cancer Cells by Means of Labeled Antibodies and Elemental (ICP-MS) Detection
- (2019) Mario Corte-Rodríguez et al. ANALYTICAL CHEMISTRY
- Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases
- (2017) Gabriele Zoppoli et al. Journal of Translational Medicine
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- Prognostic and predictive biomarkers in breast cancer: Past, present and future
- (2017) Andrea Nicolini et al. SEMINARS IN CANCER BIOLOGY
- Mass Cytometry: Single Cells, Many Features
- (2016) Matthew H. Spitzer et al. CELL
- Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay
- (2016) D. Mouttet et al. PLoS One
- Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status
- (2016) Maria Soares et al. Oncotarget
- Advantages and Disadvantages of Technologies for HER2 Testing in Breast Cancer Specimens: Table 1
- (2015) Daniela Furrer et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Breast Cancer Subtypes Predispose the Site of Distant Metastases
- (2015) Abha Soni et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2014) Sharon H. Giordano et al. JOURNAL OF CLINICAL ONCOLOGY
- Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry
- (2014) Charlotte Giesen et al. NATURE METHODS
- A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer
- (2014) Fatemeh Bahreini et al. Breast Cancer
- HER2 testing: Current status and future directions
- (2013) Edith A. Perez et al. CANCER TREATMENT REVIEWS
- Challenges in the clinical utility of the serum test for HER2 ECD
- (2012) Lian Lam et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Biomarkers for the clinical management of breast cancer: International perspective
- (2012) Neill Patani et al. INTERNATIONAL JOURNAL OF CANCER
- Current technologies for HER2 testing in breast cancer
- (2011) C.B. Moelans et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system
- (2008) Allen M Gown et al. MODERN PATHOLOGY
- Current issues in ER and HER2 testing by IHC in breast cancer
- (2008) Allen M Gown MODERN PATHOLOGY
- Human Breast Cancer Tumor Models: Molecular Imaging of Drug Susceptibility and Dosing during HER2/neu-targeted Therapy
- (2008) Michael S. Gee et al. RADIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started